Literature DB >> 17053970

Changes in subcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesioned and l-dopa-treated rats.

Maowen Ba1, Min Kong, Hongqi Yang, Guozhao Ma, Guoqiang Lu, Shengdi Chen, Zhenguo Liu.   

Abstract

Recent evidence has linked striatal amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor function to the adverse effects of long-term dopaminergic treatment in Parkinson's disease. The phosphorylation of AMPA subunit, GluR1, reflects AMPA receptor activity. To determine whether serine phosphorylation of GluR1 subunit by activation of Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) contributes to the process, we examined the effects of unilateral nigrostriatal depletion with 6-hydroxydopamine and subsequent L: -dopa treatment on motor responses and phosphorylation states. Three weeks of L: -dopa administration to rats shortened the duration of the rotational response. We found a significant reduction in the abundance of both phosphorylated GluR1 at serine-831 site (pGluR1S831) and GluR1 in the cell plasma membrane of lesioned striatum. Chronic treatment of lesioned rats with L: -dopa markedly upregulated the phosphorylation of GluR1 in lesioned striatum with a concomitant normalization of the plasma membrane GluR1 abundance, which lasted at least 1 day after withdrawal of chronic L: -dopa treatment. Our immunostaining data showed that these changes were confined to parvalbumin-positive neurons where GluR1 subunits are exclusively expressed. Both the altered motor response duration and the degree of pGluR1S831 were attenuated by the intrastriatal administration of CaMKII inhibitor KN-93. These findings suggest that activation of CaMKII contributes to both development and maintenance of motor response duration alterations, through a mechanism that involves an increase in pGluR1S831 within parvalbumin-positive neurons.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17053970     DOI: 10.1007/s11064-006-9177-9

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  43 in total

1.  "Ottorino Rossi" Award 2000. New targets for therapy in Parkinson's disease: pathogenesis and pathophysiology.

Authors:  J T Greenamyre
Journal:  Funct Neurol       Date:  2000 Apr-Jun

2.  Phosphorylation of the AMPA receptor GluR1 subunit is required for synaptic plasticity and retention of spatial memory.

Authors:  Hey-Kyoung Lee; Kogo Takamiya; Jung-Soo Han; Hengye Man; Chong-Hyun Kim; Gavin Rumbaugh; Sandy Yu; Lin Ding; Chun He; Ronald S Petralia; Robert J Wenthold; Michela Gallagher; Richard L Huganir
Journal:  Cell       Date:  2003-03-07       Impact factor: 41.582

3.  Calcium- and calmodulin-dependent phosphorylation of AMPA type glutamate receptor subunits by endogenous protein kinases in the post-synaptic density.

Authors:  Y Hayashi; A Ishida; H Katagiri; M Mishina; H Fujisawa; T Manabe; T Takahashi
Journal:  Brain Res Mol Brain Res       Date:  1997-06

4.  Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase.

Authors:  T G Banke; D Bowie; H Lee; R L Huganir; A Schousboe; S F Traynelis
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

Review 5.  Dopamine/glutamate interactions in Parkinson's disease.

Authors:  K W Lange; J Kornhuber; P Riederer
Journal:  Neurosci Biobehav Rev       Date:  1997-07       Impact factor: 8.989

6.  Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane.

Authors:  A W Dunah; D G Standaert
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

7.  Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats.

Authors:  C Marin; A Jimenez; M Bonastre; T N Chase; E Tolosa
Journal:  Synapse       Date:  2000-06-15       Impact factor: 2.562

8.  Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.

Authors:  M Lundblad; M Andersson; C Winkler; D Kirik; N Wierup; M Angela Cenci
Journal:  Eur J Neurosci       Date:  2002-01       Impact factor: 3.386

9.  Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism.

Authors:  Abigail M Brown; Ariel Y Deutch; Roger J Colbran
Journal:  Eur J Neurosci       Date:  2005-07       Impact factor: 3.386

10.  NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.

Authors:  R H Wessell; S M Ahmed; F S Menniti; G L Dunbar; T N Chase; J D Oh
Journal:  Neuropharmacology       Date:  2004-08       Impact factor: 5.250

View more
  12 in total

1.  Ca2+/calmodulin-dependent protein kinase II inhibitors disrupt AKAP79-dependent PKC signaling to GluA1 AMPA receptors.

Authors:  Ian M Brooks; Steven J Tavalin
Journal:  J Biol Chem       Date:  2010-12-14       Impact factor: 5.157

2.  Comparison of immunoreactivities of calbindin-D28k, calretinin and parvalbumin in the striatum between young, adult and aged mice, rats and gerbils.

Authors:  Eun Joo Bae; Bai Hui Chen; Bich Na Shin; Jeong Hwi Cho; In Hye Kim; Joon Ha Park; Jae Chul Lee; Hyun Jin Tae; Soo Young Choi; Jong-Dai Kim; Yun Lyul Lee; Moo-Ho Won; Ji Hyeon Ahn
Journal:  Neurochem Res       Date:  2015-02-13       Impact factor: 3.996

Review 3.  Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.

Authors:  Augusta Pisanu; Laura Boi; Giovanna Mulas; Saturnino Spiga; Sandro Fenu; Anna R Carta
Journal:  J Neural Transm (Vienna)       Date:  2018-03-14       Impact factor: 3.575

Review 4.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

5.  Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease.

Authors:  J Spampanato; X Gu; X W Yang; I Mody
Journal:  Neuroscience       Date:  2008-09-18       Impact factor: 3.590

6.  Glutamatergic mechanisms in L-DOPA-induced dyskinesia and therapeutic implications.

Authors:  Manuela Mellone; Fabrizio Gardoni
Journal:  J Neural Transm (Vienna)       Date:  2018-01-31       Impact factor: 3.575

Review 7.  Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.

Authors:  Susan Duty
Journal:  CNS Drugs       Date:  2012-12       Impact factor: 5.749

8.  Post-translational modification biology of glutamate receptors and drug addiction.

Authors:  Li-Min Mao; Ming-Lei Guo; Dao-Zhong Jin; Eugene E Fibuch; Eun Sang Choe; John Q Wang
Journal:  Front Neuroanat       Date:  2011-03-17       Impact factor: 3.856

9.  Postsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat models.

Authors:  Maowen Ba; Min Kong; Guozhao Ma
Journal:  Drug Des Devel Ther       Date:  2014-12-19       Impact factor: 4.162

10.  NMDA receptor regulation of levodopa-induced behavior and changes in striatal G protein-coupled receptor kinase 6 and β-arrestin-1 expression in parkinsonian rats.

Authors:  Na Wu; Lu Song; Xinxin Yang; Weien Yuan; Zhenguo Liu
Journal:  Clin Interv Aging       Date:  2013-03-26       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.